14:11:35 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-01-31 07:40 ET - News Release

NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliqua BioMedical, Inc. (NASDAQ:ALQA), Donegal Group, Inc. (NASDAQ:DGICA), QAD Inc. (NASDAQ:QADA), ManpowerGroup (NYSE:MAN), Acorda Therapeutics, Inc. (NASDAQ:ACOR), and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ALQA DOWNLOAD: http://Fundamental-Markets.com/register/?so=ALQA
DGICA DOWNLOAD: http://Fundamental-Markets.com/register/?so=DGICA
QADA DOWNLOAD: http://Fundamental-Markets.com/register/?so=QADA
MAN DOWNLOAD: http://Fundamental-Markets.com/register/?so=MAN
ACOR DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACOR
ARNA DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARNA

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Alliqua BioMedical, Inc. (NASDAQ:ALQA), Donegal Group, Inc. (NASDAQ:DGICA), QAD Inc. (NASDAQ:QADA), ManpowerGroup (NYSE:MAN), Acorda Therapeutics, Inc. (NASDAQ:ACOR), and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 26th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ALLIQUA BIOMEDICAL, INC. (ALQA) REPORT OVERVIEW

Alliqua BioMedical's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Alliqua BioMedical reported revenue of $4.90MM vs $4.38MM (up 12.02%) and basic earnings per share -$0.56 vs -$3.05. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Alliqua BioMedical reported revenue of $18.24MM vs $12.18MM (up 49.79%) and basic earnings per share -$10.10 vs -$11.30. Alliqua BioMedical is expected to report earnings on March 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$1.80. The estimated EPS forecast for the next fiscal year is $5.14 and is expected to report on March 6th, 2018.

To read the full Alliqua BioMedical, Inc. (ALQA) report, download it here: http://Fundamental-Markets.com/register/?so=ALQA

-----------------------------------------

DONEGAL GROUP,  INC. (DGICA) REPORT OVERVIEW

Donegal Group's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Donegal Group reported revenue of $185.72MM vs $175.31MM (up 5.93%) and basic earnings per share $0.26 vs $0.18 (up 43.65%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Donegal Group reported revenue of $688.42MM vs $636.39MM (up 8.18%) and basic earnings per share $1.16 vs $0.76 (up 53.03%). Donegal Group is expected to report earnings on February 23rd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.20. The estimated EPS forecast for the next fiscal year is $1.44 and is expected to report on February 23rd, 2018.

To read the full Donegal Group, Inc. (DGICA) report, download it here: http://Fundamental-Markets.com/register/?so=DGICA

-----------------------------------------

QAD INC.(QADA) REPORT OVERVIEW

QAD's Recent Financial Performance

For the three months ended October 31st, 2017 vs October 31st, 2016, QAD reported revenue of $76.93MM vs $69.53MM (up 10.63%) and basic earnings per share -$0.01 vs $0.08. For the twelve months ended January 31st, 2017 vs January 31st, 2016, QAD reported revenue of $277.97MM vs $277.85MM (up 0.04%) and basic earnings per share -$0.82 vs $0.48. QAD is expected to report earnings on March 21st, 2018. The report will be for the fiscal period ending January 31st, 2018. The reported EPS for the same quarter last year was $0.06. The estimated EPS forecast for the next fiscal year is -$0.02 and is expected to report on March 21st, 2018.

To read the full QAD Inc. (QADA) report, download it here: http://Fundamental-Markets.com/register/?so=QADA

-----------------------------------------

MANPOWERGROUP (MAN) REPORT OVERVIEW

ManpowerGroup's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, ManpowerGroup reported revenue of $5,464.80MM vs $5,088.20MM (up 7.40%) and basic earnings per share $2.06 vs $1.89 (up 8.99%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, ManpowerGroup reported revenue of $19,654.10MM vs $19,329.90MM (up 1.68%) and basic earnings per share $6.33 vs $5.46 (up 15.93%). ManpowerGroup is expected to report earnings on February 2nd, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $1.80. The estimated EPS forecast for the next fiscal year is $7.82 and is expected to report on February 2nd, 2018.

To read the full ManpowerGroup (MAN) report, download it here: http://Fundamental-Markets.com/register/?so=MAN

-----------------------------------------

ACRDA THERAPEUTICS, INC. (ACOR) REPORT OVERVIEW

Acorda Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Acorda Therapeutics reported revenue of $141.07MM vs $135.61MM (up 4.02%) and basic earnings per share -$0.55 vs -$0.28. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Acorda Therapeutics reported revenue of $519.60MM vs $492.66MM (up 5.47%) and basic earnings per share -$0.76 vs $0.26. Acorda Therapeutics is expected to report earnings on February 13th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.07. The estimated EPS forecast for the next fiscal year is -$0.25 and is expected to report on February 13th, 2018.

To read the full Acorda Therapeutics, Inc. (ACOR) report, download it here: http://Fundamental-Markets.com/register/?so=ACOR

-----------------------------------------

ARENA PHARMACEUTICALS, INC. (ARNA) REPORT OVERVIEW

Arena Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Arena Pharmaceuticals reported revenue of $7.95MM vs $19.24MM (down 58.69%) and basic earnings per share -$0.86 vs -$0.51. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Arena Pharmaceuticals reported revenue of $123.98MM vs $38.33MM (up 223.47%) and basic earnings per share -$0.90 vs -$4.50. Arena Pharmaceuticals is expected to report earnings on March 13th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $1.60. The estimated EPS forecast for the next fiscal year is -$2.57 and is expected to report on March 13th, 2018.

To read the full Arena Pharmaceuticals, Inc. (ARNA) report, download it here: http://Fundamental-Markets.com/register/?so=ARNA

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

 

© 2024 Canjex Publishing Ltd. All rights reserved.